SEC Tracker
Get the app

Integra Lifesciences Holdings IART

Integra LifeSciences reports Q3 results and updates 2026 guidance

Form
8-K
Filed
Importance
Routine
  1. Revenue expected between $410M and $412M for Q3 2026.
  2. Flood disruption in Cincinnati caused $7M revenue loss in Q3.
  3. Full-year revenue guidance lowered to $1.634B-$1.654B from $1.654B-$1.695B.
  4. Adjusted EPS guidance lowered to $2.30-$2.40 from $2.40-$2.50.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Integra Lifesciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Establishment Labs Holdings ESTA public float $975M, Jun 30, 2025
  2. NovoCure NVCR public float $995M, Jun 30, 2025
  3. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  4. SI-BONE SIBN public float $800M, Jun 30, 2025
  5. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.